Last Updated:


Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on lung viral defence in asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease. Synairgen is currently running a Phase II trial evaluating SNG001 in COPD patients and announced on 18 March 2020 a Phase II trial with SNG001 in COVID-19 patients to potentially assist with the global outbreak.


Burn Rate (Quarterly)

Amp Analysis

Pipeline Information

Click drug data to see upcoming trial info and prior data

Drug | Disease

Stage | Exp Date

Prior Data

SG016 / SNG001


Phase 2


IFN-β (SNG001)

Chronic Obstructive Pulmonary Disease (COPD)

Phase 2 Data


Recent Posts

See What The Community Is Saying - Click To See Full Post

SYGGF - Data from SG016 Phase ...

Summary: Data published in the peer-reviewed journal shows positive results for SNG001 in hospitalised COVID-19 patients #SYGGF "announced the publication of data from the Company’s #SG016 trial in T...

SYGGF (Synairgen) - Positive ...

#SYGGF (Synairgen) announced "positive results from interim analysis of SG015, its double-blind placebo-controlled Phase II trial of SNG001 in COPD patients announced in September, supporting the COVI...

*Disclaimer: Information provided on and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon